Cytokinetics reported additional ACACIA-HCM data showing aficamten improved cardiac structure and measures of diastolic function in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, alongside previously reported gains in symptoms and exercise capacity. In the 517-patient Phase 3 trial, 53% of patients receiving aficamten achieved meaningful improvement across at least three of five disease measures, compared with 13% on placebo. About 10% experienced a decline in heart pumping capacity, and 12 heart-failure events occurred during the study. The new analysis found improvements in wall thickness and diastolic-function measures at Week 36 and at end of treatment, which lasted up to 72 weeks. Separately, a MAPLE-HCM analysis found aficamten outperformed metoprolol across groups defined by pre-trial treatment. The findings were presented at the European Society of Cardiology Congress 2026 in Munich and published simultaneously in Circulation and the Journal of the American College of Cardiology: Heart Failure. Cytokinetics plans to submit a U.S. supplemental application for non-obstructive HCM in the fourth quarter of 2026. Aficamten, marketed as Myqorzo, is already approved for symptomatic obstructive HCM in the U.S., China, European Union and United Kingdom.